“No permanent implant” is not a regulatory shortcut: boundaries for DCB, IVL and PFA

An analytical label, not an FDA pathway

“No permanent implant” describes whether the treatment device remains in the body; it does not replace the actual mechanism, classification, indication or risk evaluation. FDA used PMA records for the representative products below, not a single pathway called no permanent implant.[2][3][4][6]

Removing the device also does not remove the treatment effect: DCB leaves drug exposure, IVL modifies a calcified lesion, and PFA creates irreversible tissue injury.[1][4][6] “No permanent hardware” therefore does not mean no long-term risk, no follow-up or no use alongside an implant.

DCB: the device exits after drug transfer to the vessel wall

FDA explains that paclitaxel-coated balloons used in peripheral arterial disease deliver paclitaxel from the balloon coating to the vessel wall to reduce restenosis risk.[1] Lutonix 035 DCB, P130024, was approved October 9, 2014. Its approval summary identifies a device-drug combination with a 2 µg/mm² drug-coating density.[2]

LEVANT 2 enrolled 543 subjects, of whom 476 were randomized (316 DCB and 160 PTA); the randomized cohort was scheduled for annual follow-up through five years.[2] FDA’s 2023 update says the totality of available data does not support an excess mortality risk from paclitaxel-coated devices, while retaining risk-benefit discussion and routine monitoring.[1] That is an updated evidence conclusion with ongoing clinical boundaries—not deletion of the safety question.

Coronary IVL: no retained IVL catheter, but an indication linked to stenting

FDA approved the Shockwave C2 Coronary IVL System, P200039, on February 12, 2021. Its indication covers lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic coronary arteries and expressly says prior to stenting.[3][4] The IVL catheter is not permanently retained, but the complete treatment strategy cannot be rewritten as stent-free.

The approval summary describes a 384-patient pivotal cohort. Thirty-day freedom from major adverse cardiovascular events was 92.2% (353/383), and device-related serious adverse events through 30 days were 2.1% (8/384).[4] The denominators differ and should remain visible; one product’s results also should not be generalized to every IVL system.

PFA leaves irreversible tissue effects—and the acquisition year matters

FDA approved the FARAPULSE PFA System, P230030, on January 30, 2024. The approval summary describes irreversible electroporation that renders targeted myocardial tissue electrically non-conductive. Risks still include perforation, tamponade, stroke, atrio-esophageal fistula, pulmonary-vein stenosis and other procedural or tissue-injury hazards.[5][6]

ADVENT enrolled 706 subjects: 80 roll-in and 626 randomized, with follow-up through 12 months.[6] That directly counters the inference that a non-retained catheter needs no systematic clinical evidence. Johnson & Johnson announced its Shockwave acquisition on April 5, 2024 at $335 per share and about $13.1 billion enterprise value, including cash acquired, then completed it May 31, 2024. Dating the transaction to 2023 is incorrect.[7][8]

Sources and reading boundary

1. FDA: paclitaxel-coated devices for peripheral arterial disease
2. FDA: Lutonix 035 DCB P130024 approval summary
3. FDA: Shockwave C2 P200039 approval order
4. FDA: Shockwave C2 P200039 approval summary
5. FDA: FARAPULSE approval announcement
6. FDA: FARAPULSE P230030 approval summary
7. Johnson & Johnson: agreement to acquire Shockwave
8. Johnson & Johnson: completion of Shockwave acquisition

This article uses representative U.S. approvals to define concepts; it is not a class-wide comparison of all DCB, IVL or PFA products. Current labeling for the specific device governs indication, contraindications, companion implants and follow-up.

The BIO angle

FAQ

Related reading

• The Century-Long Catheter Infection War: Foley Design, CAUTI and the Coating Path | BIO Insights
• Nystagmus Device Approved: After the Breakthrough, Commercialization Begins | BIO Insights
• A Double Breakthrough in Minimally Invasive Glaucoma Care: RF Ablation and Suprachoroidal Drainage | BIO Insights

Browse all insights →

Notice: This is educational industry analysis based on public FDA and company records, not medical, investment, legal, regulatory or product-selection advice. Data from representative approved products should not be generalized to an entire technology class; clinical decisions require current labeling, patient context and professional judgment.